UWA PhD Alcohol Pharmacotherapy Trends Australia 2006-2023
Ebony Quintrell's UWA PhD study analyzes 18 years of PBS data, showing naltrexone surge but only 2.9% AUD coverage—first national insights into underutilized therapies.
No reviews yet. Be the first to rate Amy!
Associate Professor Amy Page is a consultant pharmacist and qualified biostatistician at the University of Western Australia. She holds a PhD awarded in 2017 along with qualifications including MHPE, MClinPharm, GradDipBiostat, GradCertDMEd and PFHEA. Dr Page serves as Director of the Centre for Optimisation of Medicines and as Course Director for the Doctor of Pharmacy Practice and Master of Advanced Clinical Practice programs in the School of Health and Clinical Sciences. Her research focuses on deprescribing, quality use of medicines and geriatrics, with the aim of reducing medicines-related harm while balancing symptom control to align with individualised treatment goals for older people. She has secured over $17 million in funding across 35 grants and published over 180 articles, including more than 120 peer-reviewed papers. Dr Page has presented nationally and internationally on medicine safety and the quality use of medicines for older people, and her work is frequently profiled in professional and lay media.
Dr Page has held clinical roles across community, hospital, medication review, Aboriginal community-controlled health services and general practice settings. She was one of the first Australian pharmacists to work within a general practice to optimise medicines use among people with multimorbidity and polypharmacy, and she served as the inaugural Lead Pharmacist for Rehabilitation Aged and Community Care Services at Alfred Health. She is a credentialled diabetes educator and continues clinical work in community pharmacy and medication management reviews. Her contributions have been recognised with awards including the Pharmaceutical Society of Australia Pharmacist of the Year in 2024 and Young Pharmacist of the Year in 2015, the 2022 Vice Chancellor's Early Career Researcher award, the 2023 School Research Impact and Innovation award, and fellowships with the Pharmaceutical Society of Australia, the Society of Hospital Pharmacists of Australia and the Higher Education Academy. She has served on national and international policy, governance and regulatory bodies, including the Pharmacy Board of Australia and the Pharmaceutical Society of Australia's national board of directors.
Ebony Quintrell's UWA PhD study analyzes 18 years of PBS data, showing naltrexone surge but only 2.9% AUD coverage—first national insights into underutilized therapies.